What injections are available for increasing platelet count?
There are two types of injectable agents for increasing platelet count: recombinant human thrombopoietin and interleukin-11.
Recombinant human thrombopoietin is a cytokine that specifically binds to receptors on megakaryocytes in the bone marrow. It promotes the proliferation and division of megakaryocytes, leading to increased platelet production. It also accelerates the release of platelets from the bone marrow into the peripheral blood, thereby increasing the platelet count in circulation. Local use may cause allergic reactions such as skin itching and rashes. Patients with heart or cerebrovascular diseases should avoid using this agent.
Interleukin-11, also known as recombinant human interleukin-11, primarily promotes the proliferation of hematopoietic stem cells and megakaryocytes, facilitates maturation and differentiation of megakaryocytes, and enhances platelet production. Common side effects include fatigue, pain, chills, nausea, and muscle aches. In severe cases, it may lead to acute cardiac dysfunction; however, most adverse reactions are mild and quickly resolve after discontinuation of the drug. Regular blood tests are recommended during treatment, and caution should be exercised when administering this agent to patients with organic heart disease.
Recombinant human thrombopoietin and interleukin-11 should only be used under a doctor's guidance. Self-medication is not recommended to avoid potential adverse effects.